RU2015112121A - Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний - Google Patents
Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний Download PDFInfo
- Publication number
- RU2015112121A RU2015112121A RU2015112121A RU2015112121A RU2015112121A RU 2015112121 A RU2015112121 A RU 2015112121A RU 2015112121 A RU2015112121 A RU 2015112121A RU 2015112121 A RU2015112121 A RU 2015112121A RU 2015112121 A RU2015112121 A RU 2015112121A
- Authority
- RU
- Russia
- Prior art keywords
- rna
- administered
- seq
- sequence
- dose
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract 6
- 206010013774 Dry eye Diseases 0.000 claims abstract 6
- 206010015958 Eye pain Diseases 0.000 claims abstract 6
- 108091070501 miRNA Proteins 0.000 claims abstract 4
- 239000002679 microRNA Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 230000008685 targeting Effects 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Применение ми-РНК, мишенью которой является последовательность SEQ ID NO:1, для получения лекарственного средства для лечения сухих глаз и/или глазной боли, при этом ми-РНК вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.2. Применение по п. 1, при котором ми-РНК вводят в дозе примерно от 0,5 мг до примерно 1,5 мг в сутки.3. Применение по п. 1, при котором ми-РНК вводят в дозе примерно 0,6 мг или примерно 0,9 мг на глаз в сутки.4. Применение по п.1, при котором указанную ми-РНК вводят в течение 5-15 дней.5. Применение по п. 4, при котором указанную ми-РНК вводят в течение 10 дней.6. Применение по п. 1, при котором указанную ми-РНК вводят постоянно.7. Применение по п. 1, при котором указанная ми-РНК представляет собой соединение, определяемое как последовательность SEQ ID NO:2.8. Применение по п. 1, при котором указанную ми-РНК вводят местно в глаз.9. ми-РНК, мишенью которой является последовательность SEQ ID NO:1, для применения при лечении сухих глаз и/или глазной боли, при этом ми-РНК вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.10. Способ лечения сухих глаз и/или глазной боли, при этом ми-РНК, мишенью которой является последовательность SEQ ID NO:1, вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.11. Медицинский набор для введения ми-РНК, мишенью которой является последовательность SEQ ID NO:1, содержащий предлагаемую ми-РНК, мишенью которой является последовательность SEQ ID NO:1, при этом указанная доза содержит примерно от 0,1 мг до примерно 10 мг для ежедневного введения и напечатанные инструкции по введению ми-РНК, мишенью которой является последовательность SEQ ID NO:1, по пп. 1-7.
Claims (11)
1. Применение ми-РНК, мишенью которой является последовательность SEQ ID NO:1, для получения лекарственного средства для лечения сухих глаз и/или глазной боли, при этом ми-РНК вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.
2. Применение по п. 1, при котором ми-РНК вводят в дозе примерно от 0,5 мг до примерно 1,5 мг в сутки.
3. Применение по п. 1, при котором ми-РНК вводят в дозе примерно 0,6 мг или примерно 0,9 мг на глаз в сутки.
4. Применение по п.1, при котором указанную ми-РНК вводят в течение 5-15 дней.
5. Применение по п. 4, при котором указанную ми-РНК вводят в течение 10 дней.
6. Применение по п. 1, при котором указанную ми-РНК вводят постоянно.
7. Применение по п. 1, при котором указанная ми-РНК представляет собой соединение, определяемое как последовательность SEQ ID NO:2.
8. Применение по п. 1, при котором указанную ми-РНК вводят местно в глаз.
9. ми-РНК, мишенью которой является последовательность SEQ ID NO:1, для применения при лечении сухих глаз и/или глазной боли, при этом ми-РНК вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.
10. Способ лечения сухих глаз и/или глазной боли, при этом ми-РНК, мишенью которой является последовательность SEQ ID NO:1, вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.
11. Медицинский набор для введения ми-РНК, мишенью которой является последовательность SEQ ID NO:1, содержащий предлагаемую ми-РНК, мишенью которой является последовательность SEQ ID NO:1, при этом указанная доза содержит примерно от 0,1 мг до примерно 10 мг для ежедневного введения и напечатанные инструкции по введению ми-РНК, мишенью которой является последовательность SEQ ID NO:1, по пп. 1-7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1215857.2 | 2012-09-05 | ||
| GBGB1215857.2A GB201215857D0 (en) | 2012-09-05 | 2012-09-05 | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| PCT/EP2013/068245 WO2014037377A1 (en) | 2012-09-05 | 2013-09-04 | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015112121A true RU2015112121A (ru) | 2016-10-27 |
| RU2663100C2 RU2663100C2 (ru) | 2018-08-01 |
Family
ID=47136985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015112121A RU2663100C2 (ru) | 2012-09-05 | 2013-09-04 | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9808479B2 (ru) |
| EP (1) | EP2893019B1 (ru) |
| JP (2) | JP2015529210A (ru) |
| KR (1) | KR102136539B1 (ru) |
| CN (2) | CN108354944A (ru) |
| AU (1) | AU2013311781B2 (ru) |
| BR (1) | BR112015004469B8 (ru) |
| CA (1) | CA2883040C (ru) |
| CL (1) | CL2015000537A1 (ru) |
| CY (1) | CY1121000T1 (ru) |
| DK (1) | DK2893019T3 (ru) |
| EC (1) | ECSP15009391A (ru) |
| ES (1) | ES2685346T3 (ru) |
| GB (1) | GB201215857D0 (ru) |
| HK (1) | HK1212377A1 (ru) |
| HR (1) | HRP20181079T1 (ru) |
| HU (1) | HUE040096T2 (ru) |
| IL (1) | IL237389B (ru) |
| IN (1) | IN2015DN02501A (ru) |
| LT (1) | LT2893019T (ru) |
| MX (1) | MX362854B (ru) |
| PE (1) | PE20150619A1 (ru) |
| PL (1) | PL2893019T3 (ru) |
| PT (1) | PT2893019T (ru) |
| RS (1) | RS57620B1 (ru) |
| RU (1) | RU2663100C2 (ru) |
| SG (1) | SG11201501386TA (ru) |
| SI (1) | SI2893019T1 (ru) |
| WO (1) | WO2014037377A1 (ru) |
| ZA (1) | ZA201501494B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102554783B1 (ko) | 2011-06-30 | 2023-07-11 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| US10130651B2 (en) | 2015-08-07 | 2018-11-20 | Arrowhead Pharmaceuticals, Inc. | RNAi Therapy for Hepatitis B Virus Infection |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| CN113453686A (zh) | 2019-02-15 | 2021-09-28 | 诺华股份有限公司 | 治疗眼表痛的方法 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| CN114585357A (zh) * | 2019-10-04 | 2022-06-03 | 千寿制药株式会社 | 含有杂环亚基乙酰胺衍生物的药物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| EP1587574A4 (en) | 2001-12-21 | 2009-03-18 | Rhode Island Hospital | 11b-HSD SELECTIVE INHIBITORS AND METHODS OF USE |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003087368A2 (en) | 2002-04-18 | 2003-10-23 | Lynkeus Bio Tech Gmbh | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| AU2003254162A1 (en) | 2002-07-24 | 2004-02-09 | Immusol Incorporated | Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker |
| JP2005533503A (ja) | 2002-07-24 | 2005-11-10 | イミューソル インコーポレイテッド | 新規なｓｉＲＮＡ遺伝子ライブラリー、その製造方法及び使用 |
| SI2258847T1 (sl) | 2002-08-05 | 2017-08-31 | Silence Therapeutics Gmbh | Nadaljnje nove oblike molekul interferenčne RNA |
| US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| AU2003282877B9 (en) | 2002-09-25 | 2011-05-12 | University Of Massachusetts | In Vivo gene silencing by chemically modified and stable siRNA |
| NZ540779A (en) | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
| DE10322662A1 (de) | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| WO2005044976A2 (en) | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
| KR20050039573A (ko) | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| AU2004294824A1 (en) * | 2003-12-03 | 2005-06-16 | Coda Therapeutics (Nz) Ltd | Antisense compounds targeted to connexins and methods of use thereof |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005076998A2 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| US7947659B2 (en) | 2004-03-12 | 2011-05-24 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
| US7582744B2 (en) | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| CA2578064C (en) | 2004-08-23 | 2015-10-13 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| US7947660B2 (en) | 2005-03-11 | 2011-05-24 | Alcon, Inc. | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| CN101517081A (zh) * | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi介导的Gremlin抑制用于治疗眼内压相关的状况 |
| US20110160279A1 (en) | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| CN201337650Y (zh) * | 2009-01-06 | 2009-11-04 | 河北科技大学 | 一次性药用单剂量液体容器 |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
-
2012
- 2012-09-05 GB GBGB1215857.2A patent/GB201215857D0/en not_active Ceased
-
2013
- 2013-09-04 RU RU2015112121A patent/RU2663100C2/ru active
- 2013-09-04 KR KR1020157006165A patent/KR102136539B1/ko active IP Right Grant
- 2013-09-04 CN CN201810353730.8A patent/CN108354944A/zh active Pending
- 2013-09-04 DK DK13759707.6T patent/DK2893019T3/en active
- 2013-09-04 RS RS20180877A patent/RS57620B1/sr unknown
- 2013-09-04 PE PE2015000282A patent/PE20150619A1/es not_active Application Discontinuation
- 2013-09-04 AU AU2013311781A patent/AU2013311781B2/en active Active
- 2013-09-04 SI SI201331090T patent/SI2893019T1/sl unknown
- 2013-09-04 BR BR112015004469A patent/BR112015004469B8/pt active IP Right Grant
- 2013-09-04 MX MX2015002802A patent/MX362854B/es active IP Right Grant
- 2013-09-04 IN IN2501DEN2015 patent/IN2015DN02501A/en unknown
- 2013-09-04 US US14/425,459 patent/US9808479B2/en active Active
- 2013-09-04 PL PL13759707T patent/PL2893019T3/pl unknown
- 2013-09-04 CA CA2883040A patent/CA2883040C/en active Active
- 2013-09-04 PT PT13759707T patent/PT2893019T/pt unknown
- 2013-09-04 JP JP2015530372A patent/JP2015529210A/ja active Pending
- 2013-09-04 SG SG11201501386TA patent/SG11201501386TA/en unknown
- 2013-09-04 CN CN201380046215.0A patent/CN104640988A/zh active Pending
- 2013-09-04 LT LTEP13759707.6T patent/LT2893019T/lt unknown
- 2013-09-04 HU HUE13759707A patent/HUE040096T2/hu unknown
- 2013-09-04 ES ES13759707.6T patent/ES2685346T3/es active Active
- 2013-09-04 WO PCT/EP2013/068245 patent/WO2014037377A1/en active Application Filing
- 2013-09-04 EP EP13759707.6A patent/EP2893019B1/en active Active
-
2015
- 2015-02-24 IL IL237389A patent/IL237389B/en active IP Right Grant
- 2015-03-04 ZA ZA2015/01494A patent/ZA201501494B/en unknown
- 2015-03-04 CL CL2015000537A patent/CL2015000537A1/es unknown
- 2015-03-12 EC ECIEPI20159391A patent/ECSP15009391A/es unknown
-
2016
- 2016-01-05 HK HK16100039.5A patent/HK1212377A1/xx unknown
-
2018
- 2018-05-09 JP JP2018090693A patent/JP6742362B2/ja active Active
- 2018-07-11 HR HRP20181079TT patent/HRP20181079T1/hr unknown
- 2018-08-10 CY CY181100845T patent/CY1121000T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202421B2 (en) | Method of treating neurological conditions with cardiac glycosides | |
| EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| IN2014CN00562A (ru) | ||
| EA201491334A1 (ru) | Композиции и способы для лечения метаболических расстройств | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| WO2014141110A3 (en) | Aminonitriles as kynurenine pathway inhibitors | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| EA201390626A1 (ru) | Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций | |
| BR112015010396A2 (pt) | terapia de combinação | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| EA201590697A1 (ru) | Производные кетамина | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201300988A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
| MX2022000143A (es) | Metodos novedosos. | |
| RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении |